Omics-based Precision Medicine of Epilepsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03358459|
Recruitment Status : Recruiting
First Posted : November 30, 2017
Last Update Posted : November 30, 2017
|Condition or disease||Intervention/treatment|
|Epilepsy Idiopathic Clinical Disease and/or Syndrome Gene Mutation||Other: non|
Part 1: Based on already existed large samples of epilepsy clinical cases, choose 2,0000 non-acquired epilepsy patients for clinical general phenotype and middle phenotype(EEG and MRI) data collection to further multi-dimensional standardization measure and evaluate. Through metabolic detection to define micro-phenotype. Establish a standardized clinical and biological samples database.
Part 2: By NGS technology to sequence for all cases, including family members, then require genotype. To test brain tissue DNA somatic mutation, which MRI negative and had an operation. To verify the newly discovered pathogenic candidate genes and carry on functional studies. Finally, to draw epileptic genetic mutations mapping in Chinese people.
Part 3: Integrated clinical and genetic epilepsy phenotypic data, combined with neural EEG and image bitmap data points for bio-markers analysis, included early warning, classification of diagnosis, curative effect prediction and epilepsy con-morbidity disease.
|Study Type :||Observational|
|Estimated Enrollment :||10000 participants|
|Official Title:||Omics-based Precision Medicine of Epilepsy Being Entrusted by Key Research Project of the Ministry of Science and Technology of China|
|Actual Study Start Date :||November 25, 2017|
|Actual Primary Completion Date :||November 26, 2017|
|Estimated Study Completion Date :||July 1, 2018|
For diagnosis non-acquired epilepsy;
- The important bio-markers for the efficient therapy and prognosis [ Time Frame: 2017.02-2018.07 ]the gene mutation or chromosome missing or duplication
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03358459
|Contact: Wang yi, Drfirstname.lastname@example.org|
|Contact: Long Shasha, Dremail@example.com|
|Children's Hospital of Fudan University||Recruiting|
|Shanghai, Shanghai, China, 201102|
|Contact: Wang yi, Dr 86+13564766228 firstname.lastname@example.org|
|Principal Investigator:||Wang yi, Dr||leader|